Physician profile
Kim Margolis
NPI 1124039037
$1,780.38
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $791 · 2020: $412 · 2021: $577.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $1,006.06 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $287.64 | 2019-2021 | |
| Amgen INC. | $232.19 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $115.73 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $27.60 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.93 | 2021 | |
| Alexion Pharmaceuticals, INC. | $23.41 | 2021 | |
| Travere Therapeutics, INC. | $19.48 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.89 | 2021 | |
| Glaxosmithkline, LLC. | $14.69 | 2021 | |
| Shire North American Group INC | $12.76 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kim Margolis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.